Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography

Lyrdal, David; Boijsen, Marianne; Suurküla, Madis; Lundstam, Sven; Stierner, Ulrika

doi:10.1097/mnm.0b013e32832cc220

Cited by 54 publications

(37 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FDG-PET has the advantage, compared with RECIST evaluation, to be not limited to soft lesions; thus, it was possible to detect a decrease in glucose uptake to 82% (53-101%) in skeletal lesions as well [149] . Vercellino et al [150] assessed 11 patients with mRCC who completed at least two cycles of sunitinib and found that early FDG-PET/CT findings, after one cycle of sunitinib, were con- sistent with later CT results in 9 of 11 assessable patients; interestingly, of the other 2 patients that showed a metabolic partial response on PET and stable disease on CT, one achieved a partial response later on, suggesting that metabolic early changes are an indication of sunitinib activity [150] .…”

Section: Antiangiogenetic Therapy Assessmentmentioning

confidence: 98%

“…Lyrdal et al [149] evaluated the early effects of sorafenib in 10 mRCC patients by using FDG-PET combined with CT. After 1-2 months, the mean glucose uptake in soft lesions decreased to 71% (32-108%); in these lesions the sum of the diameters measured by CT decreased to 80% (57-94%) of the initial value according to RECIST criteria. FDG-PET has the advantage, compared with RECIST evaluation, to be not limited to soft lesions; thus, it was possible to detect a decrease in glucose uptake to 82% (53-101%) in skeletal lesions as well [149] .…”

Section: Antiangiogenetic Therapy Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances

Sacco¹,

Pinto²,

Totaro³

et al. 2010

Urol Int

View full text Add to dashboard Cite

Background and Aim: Renal cell carcinoma (RCC) is the 13th most common cancer worldwide and accounts for 4% of all adult malignancies. Herein the state of the art and recent advances in cross-sectional radiological imaging applied to RCC are reviewed, including ultrasonography, computed tomography, magnetic resonance imaging, and positron emission tomography. Methods: Literature search of peer-reviewed papers published by October 2010. Results: In front of more conventional and widespread imaging tools, such as ultrasonography and computed tomography, an array of newer and attractive radiological modalities are under investigation and show promise to improve our ability to noninvasively detect renal tumors and its recurrences, accurately assess the extent of the disease, and reliably evaluate treatment response, particularly in the era of antiangiogenetic therapy. Conclusions: Recent major advances in radiological imaging techniques have considerably improved our ability to diagnose, stage and follow-up RCC. Further studies are needed to evaluate the potential of most recent and still investigational imaging tools.

show abstract

Section: Antiangiogenetic Therapy Assessmentmentioning

confidence: 98%

Section: Antiangiogenetic Therapy Assessmentmentioning

confidence: 99%

Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances

Sacco¹,

Pinto²,

Totaro³

et al. 2010

Urol Int

View full text Add to dashboard Cite

show abstract

“…46 These data are currently limited for mRCC patients, but the technique appears to be promising. 45,47,48 FDG-PET scans reflect changes in the metabolic activity of experimental RCC in preclinical in vivo models that are treated with mTOR inhibitors. 49 Since HIF is regulated by mTOR and given its major effects on glucose metabolism in clear-cell RCC, FDG-PET scans may provide valuable prognostic data for patients treated with mTOR inhibitors or even help select it for second-line targeted agents, which may be used following treatment with tyrosine kinase inhibitors.…”

Section: Diagnostic Implicationsmentioning

confidence: 99%

Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications

Pinthus

Whelan

Gallino

et al. 2013

CUAJ

View full text Add to dashboard Cite

Central to the malignant behaviour that endows cancer cells with growth advantage is their unique metabolism. Cancer cells can process nutrient molecules differently from normal cells and use it to overcome stress imposed on them by various therapies. This metabolic conversion is controlled by specific genetic mutations that are associated with activation of oncogenes and loss of tumour suppressor proteins. Understanding these processes is important as it can lead to the discovery of biomarkers that can predict the aggressiveness of the disease and its response to therapy, and even more importantly, to the development of novel therapeutics. A classic tumour in this respect is clear-cell renal cell carcinoma (RCC). In this review, we will begin with a brief summary of normal cellular bioenergetic pathways, which will be followed by a description of the characteristic metabolism of glucose and lipids in clear-cell RCC cells and its clinical implications. Data relating to the potential effect of dietary nutrients on RCC will also be reviewed along with potential therapies targeted at interrupting specific metabolic pathways in clear-cell RCC.

show abstract

“…In another trial including 10 patients with 52 metastatic lesions, FDG-PET/CT was performed prior to and 1-2 months after initiation of treatment with sorafenib [52] . It was shown that a significant decrease in glucose uptake was already present in all lesions independent of their location -soft tissue or skeletal system -after 1 month of treatment.…”

Section: Response Assessmentmentioning

confidence: 99%

Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society

et al. 2010

View full text Add to dashboard Cite

Introduction: Imaging studies are an integral and important diagnostic modality to stage, to monitor and follow-up patients with metastatic urogenital cancer. The currently available guidelines on diagnosis and treatment of urogenital cancer do not provide the clinician with evidence-based recommendations for daily practice. Objectives: To develop scientifically valid recommendations with regard to the most appropriate imaging technique and the most useful time interval in metastatic urogenital cancer patients undergoing systemic therapy. Methods: A systematic literature review was performed searching MedLine, Embase and Web of Science databases using the terms prostate, renal cell, bladder and testis cancer in combination with the variables lymph node, lung, liver, bone metastases, chemotherapy and molecular therapy, and the search terms computed tomography, magnetic resonance imaging and positron emission tomography were applied. A total of 11,834 records were retrieved from all databases. The panel reviewed the records to identify articles with the highest level of evidence using the recommendation of the US Agency for Health Care Policy and Research. Conclusions: Contrast-enhanced computed tomography remains the standard imaging technique for monitoring of pulmonary, hepatic and lymph node metastases. Bone scintigraphy is still the most widely used imaging technique for the detection and follow-up of osseous lesions. For clinical trials it might be replaced by either PET-CT or MRI of the skeletal axis. Response assessment for patients treated with cytotoxic regime is best performed by the RECIST/WHO criteria; treatment response to molecular triggered therapy is best assessed by CT evaluating decrease in tumor size and density. Cross-sectional imaging studies for response assessment might be obtained after each 2 cycles of systemic therapy to early stratify responders from non-responders.

show abstract

Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography

Abstract: An early decrease in the mean glucose uptake was found in both soft and skeletal lesions after treatment with sorafenib. FDG-PET thus seems to be advantageous, compared with RECIST evaluation, which is limited to soft lesions.

Cited by 54 publications

References 18 publications

Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances

Imaging of Renal Cell Carcinoma: State of the Art and Recent Advances

Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications

Imaging Studies in Metastatic Urogenital Cancer Patients Undergoing Systemic Therapy: Recommendations of a Multidisciplinary Consensus Meeting of the Association of Urological Oncology of the German Cancer Society

Contact Info

Product

Resources

About